364 filings
Page 4 of 19
8-K
cvpt1 055wzs2
17 Dec 20
Departure of Directors or Certain Officers
4:55pm
8-K
luuusz0zxwdb 6dof
7 Dec 20
BioCryst Announces $325 Million of Funding from Royalty Pharma and Athyrium Capital Management
9:34am
8-K
tb4g7 8ct
4 Dec 20
BioCryst Announces FDA Approval of ORLADEYOâ„¢ (berotralstat), First Oral, Once-daily Therapy to Prevent Attacks in Hereditary Angioedema Patients
12:00am
8-K
mvwd drspd
5 Nov 20
BioCryst Reports Third Quarter 2020 Financial Results and Upcoming Key Milestones
7:12am
8-K
7wp6k8vb2db8afzdh2
30 Sep 20
Regulation FD Disclosure
7:10am
8-K
6f1ir9
3 Sep 20
U.S. Government Exercises Option To Purchase Additional RAPIVAB® from BioCryst for Delivery to Strategic National Stockpile
7:06am
8-K
2a49be
31 Aug 20
NIAID Awards BioCryst New $44 Million Contract to Advance Development of Galidesivir
11:21am
8-K
1ptt4
31 Aug 20
Regulation FD Disclosure
7:04am
8-K
19wuqd bzzs7
6 Aug 20
BioCryst Reports Second Quarter 2020 Financial Results and Upcoming Key Milestones
7:25am
8-K
g9wvtav809q
3 Aug 20
Regulation FD Disclosure
7:14am
8-K
nnfxgcvdzdq8rx 4j0u
1 Jun 20
Entry into a Material Definitive Agreement
8:30am
8-K
aqpv9
13 May 20
Departure of Directors or Certain Officers
4:15pm
8-K
sdgamabsv r4eht7na
6 May 20
BioCryst Reports First Quarter 2020 Financial Results and Upcoming Key Milestones
7:15am
8-K
jxjw30mjkms 4f8qm0ol
10 Apr 20
BioCryst Begins Clinical Trial with Galidesivir for Treatment of Patients with COVID-19
12:00am
8-K
uvqzvx0 nreobp
2 Apr 20
BioCryst Appoints Anthony Doyle Chief Financial Officer
7:55am
8-K
0udqztf5fs1re2d
30 Mar 20
Other Events
7:20am
8-K
goy0bvg5qgmoviqpjm
10 Mar 20
Termination of a Material Definitive Agreement
9:26am
8-K
hub5x
5 Mar 20
BioCryst Reports Fourth Quarter and Full Year 2019 Financial Results and Upcoming Key Milestones
7:24am
8-K
vjxkwsg2tf
5 Mar 20
BioCryst Begins Proof of Concept Trial in PNH Patients With Oral Factor D Inhibitor, BCX9930
7:24am
8-K
dam3ggy2lyp0
25 Feb 20
BioCryst Appoints Alan G. Levin to Board of Directors
7:05am